Last reviewed · How we verify
Auto-injector with exenatide suspension — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Auto-injector with exenatide suspension (Auto-injector with exenatide suspension) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Auto-injector with exenatide suspension TARGET | Auto-injector with exenatide suspension | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Auto-injector with exenatide suspension CI watch — RSS
- Auto-injector with exenatide suspension CI watch — Atom
- Auto-injector with exenatide suspension CI watch — JSON
- Auto-injector with exenatide suspension alone — RSS
Cite this brief
Drug Landscape (2026). Auto-injector with exenatide suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/auto-injector-with-exenatide-suspension. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab